LMP7
- Known as:
- LMP7
- Catalog number:
- Y214149
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- LMP7
Related genes to: LMP7
- Gene:
- PSMB8 NIH gene
- Name:
- proteasome subunit beta 8
- Previous symbol:
- LMP7
- Synonyms:
- RING10, D6S216E, PSMB5i, beta5i
- Chromosome:
- 6p21.32
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-25
- Date modifiied:
- 2019-04-23
Related products to: LMP7
Related articles to: LMP7
- Long non-coding RNA PSMB8-AS1 involvement in heart failure (HF) following acute myocardial infarction (AMI) remains unclear. - Source: PubMed
Publication date: 2026/04/15
Wu WenwuChai Miaomiao - Proton pump inhibitors (PPIs) are an effective first-line treatment for eosinophilic esophagitis (EoE). However, half of the patients are refractory to PPI therapy, and predictive markers for therapy decision are lacking. Thus, this study aimed to investigate the differences in esophageal immunologic transcriptome between PPI-non-responders and PPI-responders and identify molecular biomarkers to guide therapy decisions. Forty-eight pediatric EoE patients were enrolled and classified due to PPI-therapy response. Pre-treatment esophagus biopsy was collected for gene expression analysis, differentially expressed genes (DEGs) between PPI-responders and non-responders were identified, followed by gene enrichment and protein-protein interaction network analyses. Expression of identified hub genes was confirmed by immunohistochemistry in an extended cohort comprising 62 patients. PPI-non-responders and responders exhibit a partially different transcriptomic profile, as 12 DEGs were up-regulated and one down-regulated. These DEGs are closely related to antigen processing and presentation function. PSMB8 was identified as a hub gene differing between these two groups, and immunohistochemistry confirmed significantly increased expression in PPI-non-responders (P < 0.0001). Notably, receiver operating characteristic curves curve analysis of PSMB8 reveals it as highly predictive for PPI response (sensitivity/specificity: 0.61/1.00). PPI-non-responding EoE patients exhibited a more profound dysregulation of gene expression. PSMB8 represents a promising esophageal biomarker for predicting therapy response in pediatric EoE. - Source: PubMed
Wei XinyiDegen SabrinaHironimus TheresaRechenauer TobiasYankouskaya KatharinaRückel AlineSchmid MargitRieger DanielEhrsam ChristophRegensburger Adrian PSchnell AlexanderRabe AnjaSchmidt-Choudhury AnjonaTannapfel AndreaDe Laffolie JanSchumann StefanSchwerd TobiasHoelz HannesAllabauer IdaGupta PoojaKrebs WolfgangHartmann ArndtWoelfle JoachimRieker RalfHoerning Andre - Hepatocellular carcinoma (HCC) is a highly malignant tumour with a poor prognosis and few effective treatment options. Development of resistance to conventional therapies and occurrence of severe side effects highlight the urgent need for novel, low-toxicity interventions. Natural products are promising candidates for HCC drug development thanks to their multi-target activity and favourable safety profiles. Previous studies reported that Lingonberry extract, a bioactive natural product, inhibits proliferation of HepG cells. However, the key molecular targets and underlying anticancer mechanisms remain unclear. In this study, we analysed gene chip data from Lingonberry extract-treated HepG tumour-bearing mice using bioinformatics tools, employing a cross-species, multi-level screening strategy to identify PSMB8 as the core regulatory gene. In vitro functional validations (Western blotting, RT-PCR, CCK-8 assay, colony formation assay, flow cytometry and TUNEL staining) confirmed these findings. Downregulating PSMB8 was found to effectively induce late apoptosis in HepG cells, and Lingonberry extract was found to significantly reduce PSMB8 protein expression. This study identifies PSMB8 as a key mediator of the anticancer effect of Lingonberry extract in HepG cells. It provides a reliable methodological reference for screening anticancer targets of natural products and supports further exploration of Lingonberry extract as a potential adjuvant/lead compound for HCC. - Source: PubMed
Publication date: 2026/03/18
Zhu LiangyuZhang ZhiZhang YandongWei DianwenWang ZhenyuZhou Liping - Long non-coding RNAs (lncRNAs) are important regulators of oncogenesis. In this study, we investigated the tumor-promoting role and prognostic value of the lncRNA PSMB8-AS1 in renal cell carcinoma (RCC). Using lncRNA microarray analysis, we identified PSMB8-AS1 as a candidate gene associated with disease progression and immune checkpoint inhibitor resistance. We examined PSMB8-AS1 expression in tumors and adjacent normal renal tissues from 192 patients with RCC. In vitro functional assays were performed to assess their role in cell proliferation and invasion. We also conducted bioinformatics and luciferase reporter assays to clarify the interaction between miR-204-5p/miR-211 and the transcription factor TFAP2A. PSMB8-AS1 was significantly overexpressed in clear cell RCC (ccRCC) tissues and correlated with poor prognosis. Knockdown experiments revealed that PSMB8-AS1 promoted proliferation and invasion. Mechanistically, PSMB8-AS1 functions as a competing endogenous RNA, sponging miR-204-5p/miR-211 and enhancing TFAP2A expression. These findings suggest that PSMB8-AS1 represents a promising biomarker for postoperative ccRCC recurrence. - Source: PubMed
Publication date: 2026/03/11
Baba ChiekoHirata HiroshiHiyoshi KoichiroTokunaga TakanoriFujii NakanoriShimizu KosukeKobayashi KeitaHayano TakahideAsai YoshiyukiShiraishi Koji - Oral squamous cell carcinoma (OSCC) exhibits significant cellular heterogeneity and metabolic reprogramming that influence tumor progression and therapeutic responses. However, the molecular mechanisms underlying these processes remain poorly understood. - Source: PubMed
Publication date: 2026/02/28
Meng LeileiWen Wenjie